Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,489
archived clinical trials in
Endometrial Cancer

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Norfolk, VA
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Tucson, AZ
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Honolulu, HI
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Arlington Heights, IL
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Niles, IL
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Niles, IL
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Detroit, MI
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Burnsville, MN
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Burnsville, MN
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Edina, MN
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Edina, MN
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Maplewood, MN
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Maplewood, MN
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Saint Paul, MN
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Woodbury, MN
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Woodbury, MN
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
St. Louis, MO
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Morristown, NJ
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
mi
from
Cleveland, NC
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
mi
from
Cleveland, NC
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Durham, NC
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Eugene, OR
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Eugene, OR
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Springfield, OR
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Springfield, OR
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Tualatin, OR
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Tualatin, OR
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Austin, TX
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Bedford, TX
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Tyler, TX
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Newport News, VA
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Virginia Beach, VA
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Vancouver, WA
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
mi
from
Arlon,
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
mi
from
Arlon,
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Central Georgia Gynecologic Oncology
mi
from
Macon, GA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Central Georgia Gynecologic Oncology
mi
from
Macon, GA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Methodist West Hospital
mi
from
West Des Moines, IA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Methodist West Hospital
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials